Abstract: Stereocontrolled syntheses of biotin-labeled oligosaccharide portions containing the Galβ1-3GalNAc core of the TES-glycoprotein antigen obtained from larvae of the parasite Toxocara and their analogues have been accomplished. Trisaccharides Fuc2Meα1-2Gal4Meβ1-3GalNAcα1-OR (A), Fucα1-2Gal4Meβ1-3GalNAcα1-OR (B), Fuc2Meα1-2Galβ1-3GalNAcα1-OR (C), Fucα1-2Galβ1-3GalNAcα1-OR (D) and a disaccharide Fuc2Meα1-2Gal4Meβ1-OR (E) (R = biotinylated probe) were synthesized by block synthesis using 5-(methoxycarbonyl)pentyl-2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(13)-2-azide-4-O-benzyl-2-deoxy-α-D-galactopyranoside as a common glycosyl acceptor. We examined the antigenicity of these five oligosaccharides by enzyme linked immunosorbent assay (ELISA). Our results demonstrate that the O-methyl groups in these oligosaccharides are important for their antigenicity and the biotinylated oligosaccharides A, B, C and E have high serodiagnostic potential to detect infections caused by Toxocara larvae.
Introduction
In the course of our studies on unique glycoconjugates found in parasites, we have synthesized various glycosphingolipids and carbohydrate portions of glycoproteins with the aim of elucidating the mechanisms of host-parasite interactions [1] [2] [3] [4] [5] [6] [7] . In previous studies we have synthesized unusual carbohydrates from the parasites Echinococcus multilocularis [1, 3, 6] , Schistosoma mansoni [2] and porcine roundworm (nematode) Ascaris suum [7] . In this paper we describe the synthesis of the carbohydrate portion of glycoproteins from Toxocara canis and T. cati. T. canis and T. cati are parasitic roundworms and are widely distributed in dogs and cats. Both nematodes cause severe infections in a human host affecting eyes, liver and the central nervous system [8, 9] .
Khoo et al., isolated Toxocara excretory-secretory (TES) antigen, a family of glycoproteins that are heavily O-glycosylated from the culture media of T. canis and T. cati larvae [10] . The TES antigen of T. canis is a mixture of mucin-type glycoproteins, containing a Fuc1-2Gal1-3GalNAc structure, and it has been found that the fucose part was O-methylated at the 2-position and approximately 50% of the galactose part was O-methylated at the 4-position, i.e., it contains the following two sequences Figure 1 ) and studied their antigenicity [11, 12] . The results showed that the sera from infected patients recognized the DiM more strongly than MoM α,β [11] . However, the both groups have not studied the effects of the di-O-methylated trisaccharide. In this paper we report the synthesis of biotin-tagged oligosaccharides A-E (Figure 2 ), two glycan portions of the glycoprotein antigen of T. canis (A and C) and three analogues (B, D and E), to elucidate the antigenicity of the oligosaccharides against sera of T. canis infected patients by enzyme-linked immunosorbent assay (ELISA). 
Results and Discussion

Chemical Synthesis
Syntheses of the target oligosaccharides A-E:
In all cases we selected 5-(methoxycarbonyl)pentyl group as the protecting group of reducing end, because this group can be conveniently used for conjugation with biotin for the use in ELISA assay as previously shown by us [1] . The synthetic routes for target compounds A-E are outlined in Schemes 1-5.
Monosaccharide derivative 3 was chosen as a common acceptor for the synthesis of oligosaccharides A-D (Scheme 1). Galactopyranosyl donor 2 was obtained from phenyl 3,6-di-O-benzyl-2-O-benzoyl-1-thio-β-D-galactopyranoside (1) [3] , by methylation using methyl iodide. Glycosylation of 2 with 3 [1] in the presence of N-iodosuccinimide (NIS)/trifluoromethanesulfonic acid (TfOH) [13] and AW-300 molecular sieves (MS AW-300) in CH 2 Cl 2 afforded desired disaccharide (4) in 68% yield. The nature of the new glycosidic linkage was determined by the vicinal coupling constant of the anomeric proton (H-1 of Gal, δ = 4.79 ppm, J = 8.0 Hz). Removal of the benzoyl groups in 4 under Zemplén conditions gave disaccharide acceptor 5 which was used directly for the next glycosylation step. To prepare the Fucα1-2Gal sequence α-stereoselectively, we selected 3,4-di-acyl protected fucosyl donor 7 [14] , which was obtained from 6 [11] by benzoylation. Previous studies have indicated that 3,4-di-acyl-protected fucopyranosyl donors induce high α-selectivity in fucosylation [2] . Glycosylation of 5 with 7 in the presence of methyl trifluoromethanesulfonate (MeOTf) [15] , tri-tert-butyl pyridine (TTBP) and MS AW-300 in CH 2 Cl 2 afforded desired trisaccharide (8) in 73% yield. The nature of the new glycosidic linkage was determined by the coupling constant of anomeric proton (H-1 of Fuc, δ = 5.67 ppm, J = 3.7 Hz). Global deprotection was performed by a combination of protection/deprotection steps. At first, the benzylidene acetal of 8 was removed by acidic hydrolysis followed by O-acetylation using acetic anhydride in pyridine to afford 9 in 87% yield. Next, the azide group was converted to an acetamide by reduction with Zn/Cu AcOH in the presence of acetic anhydride. The obtained N-acylated product 9 was debenzylated by catalytic hydrogenolysis using Pearlman's catalyst followed by O-acetylation to give 10 (52%), which was deacetylated to produce deprotected trisaccharide 11 in 96% yield. The 5-(methoxycarbonyl)pentyl glycoside 11 was converted into the ethylenediamine monoamide by exposure to ethylenediamine and conjugated to biotin to afford trisaccharide-biotin conjugate A in 94% yield (Scheme 1).
Scheme 1. Synthesis of di-methylated trisaccharide A.
Non-methylated fucopyranosyl donor 13 was synthesized from known donor 12 [16] by two-step procedure (Scheme 2). Hydrolysis of the isopropylidene group in 12 with aqueous AcOH and subsequent benzoylation produced fucopyranosyl donor 13. Trisaccharide 14 was synthesized by a coupling of the fucopyranosyl donor 13 with the disaccharide acceptor 5. The presence of an α fucosidic linkage in 14 was indicated by a doublet at δ 5.71 ppm showing small homonuclear coupling constant of 3.3 Hz in the 1 H-NMR spectrum. Deprotection and biotinylation were performed as described for compound A to provide target trisaccharide B (Scheme 2).
Scheme 2. Synthesis of mono-methylated trisaccharide B.
The synthesis of the trisaccharide C is outlined in Scheme 3. As C does not contain the O-methyl substitution in the galactose residue, we chose phenyl 3,4,6-tri-O-benzyl-2-O-benzoyl-1-thio-β-Dgalactopyranoside (18) [17] as a galactosyl donor. Glycosylation of acceptor 3 with donor 18 in the presence of NIS/TfOH provided disaccharide 19 in 68% yield. Selective removal of the benzoyl group in 19 with NaOMe produced disaccharide acceptor 20. Fucosylation of 20 with the donor 7 afforded trisaccharide 21, whose benzylidene acetal was removed as described for 8 and 14 to give 22 in 88% yield. Reduction of the azide group together with removal of benzyl groups of 22 was initially performed as described for compounds 9 and 15 using Zn/Cu and Pd(OH) 2 . However, this resulted only in a 24% yield of 23. In contrast, significantly improved yield was obtained by catalytic hydrogenation of 22 with Pd-C followed by acetylation to produce the desired trisaccharide 23 in 60% yield. Deacylation and biotinylation were performed as described for compound A to give target trisaccharide C (Scheme 3). Non-methylated trisaccharide D was synthesized from the glycosyl donor 13 and acceptor 20 as described for compound C in a good yield (Scheme 4).
Dimethylated disaccharide E, which does not contain a GalNAc residue was synthesized from galactosyl acceptor 30 with the fucosyl donor 7 as outlined in Scheme 5. Compound 30 was obtained by coupling of galactose-based thiophenyl glycoside 2 to methyl 6-hydroxyhexanoate and subsequent debenzoylation using standard conditions. Glycosylation of the acceptor 30 with 7 in the presence of MeOTf and TTBP afforded desired disaccharide 31 in 72% yield. Unfortunately, the anomeric ratio of the fucopyranosyl linkage was 10:1 (α:β, from 1 H-NMR). Although we cannot properly explain the reason of it, we presume the influence by the absence of a GalNAc derivative in monosaccharide acceptor 30. Deprotection of benzyl groups by catalytic hydrogenolysis using Pearlman's catalyst provided 32. It was possible to separate the major α-anomer form the minor β-glycoside at this stage. Deacylation and biotinylation were performed as described for compound A to provide target trisaccharide E in a good yield (Scheme 5). 
Antigenicity of Oligosaccharides by ELISA
The reactivity of the five biotin-labeled oligosaccharides A (natural), B, C (natural), D and E to patients' sera was examined using streptavidin-coated microplates. In four of the five oligosaccharides, except for D, the antibody response of the T. canis-infected patient group (Tc) was significantly high compared with that of the normal healthy (N) group (Figure 3) . However, the non-methylated trisaccharide D did not show any antigenicity to the patients' sera. This is in contrast to previous findings by Kosma and Maizels, who have reported marked differences in the antigenicity between dimethylated disaccharide (DiM) and monomethylated trisaccharide (MoMα,β in the form of BSA conjugates [11] . Our study indicates that not only the natural monomethylated trisaccharide C containing a mono-Fuc2Me moiety but also non-natural trisaccharide B containing a mono-Gal4Me moiety have the antigenicity. Moreover, the antigenicity of di-methylated trisaccharide A was stronger than that of di-methylated disaccharide E indicating that the GalNAc portion contributes to the antigenicity. Significant differences of A-C and E were observed between Tc patient group and N group (p < 0.05, Student's t test). 
Experimental
General Procedures
Optical rotations were measured with a Jasco P-1020 digital polarimeter (Tokyo, Japan). 1 H (500 MHz) and 13 C-NMR (125 MHz) spectra were recorded with a Varian 500 FT NMR spectrometer (Palo Alto, CA, USA). Me 4 Si and acetone were used as internal standards for CDCl 3 and D 2 O, respectively. MALDI-TOFMS was recorded on an AB SCIEX Voyager RP mass spectrometer (Framingham, MS, USA). High-resolution mass spectra were recorded on a JEOL JMS-700 (Tokyo, Japan) under FAB conditions. TLC was performed on Silica Gel 60 F254 (E. Merck, Darmstadt, Germany) with detection by quenching of UV fluorescence and by charring with 10% H 2 SO 4 . Column chromatography was carried out on Silica Gel 60. [11] , were prepared as reported. (2) . Sodium hydride was added portionwise to a stirred mixture of compound 1 (253 mg, 0.45 mmol), MeI (56.5 μL, 0.91 mmol) and n-Bu 4 NBr (176 mg, 0.56 mmol) in DMF (5.0 mL) at −15 °C. The mixture was stirred for 3 h at −15 °C, and MeOH was added dropwise to destroy excess NaH. The mixture was diluted with EtOAc, washed with water, dried (MgSO 4 ), and concentrated in vacuo. The product was purified by silica gel column chromatography (6:1 hexane-ethyl acetate) to give 2 (234 mg, 90%). [α D +50.6 (c 1.0, CHCl 3 ). 
5-(Methoxycarbonyl)pentyl 2-O-benzoyl-3,6-di-O-benzyl-4-O-methyl-β-D-galacto-pyranosyl-(1→3)-2-azide-4,6-O-benzylidene-2-deoxy-α-D-galactopyranoside (4)
. A mixture of 2 (203 mg, 0.37 mmol), 3 (125 mg, 0.30 mmol) and powdered MS AW300 (300 mg) in dry CH 2 Cl 2 (3 mL) was stirred under Ar atmosphere for 2 h at room temperature, then cooled to −40 °C. NIS (160 mg, 0.71 mmol) and TfOH (6.3 μL, 71.2 μmol) were added to the mixture, which was stirred for 1 h at −40 °C, then neutralized with Et 3 N. The precipitates were filtered off and washed with CHCl 3 . The combined filtrate and washings were successively washed with saturated aqueous Na 2 S 2 O 3 and water, dried (MgSO 4 ), and concentrated. The product was purified by silica gel column chromatography (5:2 hexane-ethyl acetate) to give 4 (178 mg, 68%).
[α] D +94.6 (c 1.0, CHCl 3 ). 
5-(Methoxycarbonyl)pentyl 3,6-di-O-benzyl-4-O-methyl-β-D-galactopyranosyl-(1→3)-2-azide-4,6-Obenzylidene-2-deoxy-α-D-galactopyranoside (5)
.
Phenyl 3,4-di-O-benzoyl-2-O-methyl-1-thio-β-L-fucopyranoside (7)
. A solution of 6 (616 mg, 2.28 mmol) and benzoyl chloride (793 μL, 6.84 mmol) in pyridine (8 mL) was stirred for 16 h at room temperature. After completion of the reaction, the mixture was poured into ice H 2 O and extracted with CHCl 3 . The extract was washed sequentially with 5% HCl, aq NaHCO 3 , and brine, dried (MgSO 4 ), and concentrated. The product was purified by silica gel column chromatography (10:1 hexane-ethyl acetate) to give 7 (976 mg, 90%). 
5-(Methoxycarbonyl)pentyl 3,4-di-O-benzoyl-2-O-methyl-α-L-fucopyranosyl-(1→2)-3,6-di-O-benzyl-4-Omethyl-β-D-galactopyranosyl-(1→3)-2-azide-4,6-O-benzylidene-2-deoxy-α-D-galactopyranoside (8).
A mixture of 5 (98.3 mg, 0.13 mmol), 7 (121 mg, 0.25 mmol) and MS AW300 (200 mg) in dry CH 2 Cl 2 -Et 2 O (1:1, 2.0 mL) was stirred for 2 h at room temperature. MeOTf (120 μL, 1.06 mmol) and TTBP (93.5 mg, 0.38 mmol) were added, and the mixture was stirred for 14 h at room temperature, then neutralized with Et 3 N. The precipitates were filtrated off and washed with CHCl 3 . The combined filtrate and washings were washed with water, dried (MgSO 4 ), and concentrated. The product was purified by silica gel column chromatography (3:2 hexane-EtOAc) to give 8 (105 mg, 73%). 
5-(Methoxycarbonyl)pentyl 3,4-di-O-benzoyl-2-O-methyl-α-L-fucopyranosyl-(1→2)-3,6-di-O-benzyl-4-O-methyl-β-D-galactopyranosyl-(1→3)-4,6-di-O-acetyl-2-azide-2-deoxy-α-D-galacto-pyranoside (9).
A solution of 8 (167 mg, 0.15 mmol) in 80% AcOH (5.0 mL) was stirred at 70 C for 2 h, then diluted with toluene and concentrated. The residue was acetylated with acetic anhydride (3.0 mL) in pyridine (5.0 mL). After the reaction was quenched with MeOH, toluene was added and co-evaporated several times. The product was purified by silica gel column chromatography (3:2 hexane-ethyl acetate) to give 9 (145 mg, 87%). (10) . A mixture of 9 (145 mg, 0.13 mmol) and Zn-Cu (600 mg) in THF-AcOH-Ac 2 O (3:2:1, 6.0 mL) was stirred for 30 min. at room temperature. After completion of the reaction, the mixture was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (6:1 toluene-acetone) to give an acetamide compound (128 mg). A solution of this compound in THF (2.0 mL) was hydrogenolysed (0.4 MPa) under hydrogen in the presence of 10% Pd/C (100 mg) for 2 h at room temperature. The mixture was filtered and concentrated, and the product was purified by silica gel column chromatography (2:1 toluene-acetone) to give 10 (64.1 mg, 52%). (13) . A solution of 12 (985 mg, 2.55 mmol) in 80% AcOH (20 mL) was stirred at 70 C for 2 h, then diluted with toluene and concentrated. The residue was benzoylated with benzoyl chloride (887 μL, 7.65 mmol) in pyridine (20 mL). After the reaction was quenched with MeOH, the mixture was concentrated by repeated co-evaporation with toluene. The product was purified by silica gel column chromatography (10:1 hexane-ethyl acetate) to give 13 (1.31 g, 93%). (14) . 
5-(Methoxycarbonyl
)pentyl 3,4-di-O-benzoyl-2-O-methyl-α-L-fucopyranosyl-(1→2)-4-O-methyl-β-D- galactopyranosyl-(1→3)-4,6-di-O-acetyl-2-acetamide-2-deoxy-α-D-galactopyranoside
5-(Methoxycarbonyl)pentyl 2-O-methyl-α-L-fucopyranosyl-(1→2)-4-O-methyl-β-D-galactopyranosyl-(1→3)-2-acetamide-2-deoxy-α-D-galactopyranoside (11)
Phenyl 3,4-di-O-benzoyl-2-O-benzyl-1-thio-β-L-fucopyranoside
5-(Methoxycarbonyl)pentyl 3,4-di-O-benzoyl-2-O-benzyl-α-L-fucopyranosyl-(1→2)-3,6-di-O-benzyl-4-O-methyl-β-D-galactopyranosyl-(1→3)-2-azide-4,6-O-benzylidene-2-deoxy-α-D-galactopyranoside
5-(Methoxycarbonyl)pentyl 3,4-di-O-benzoyl-2-O-benzyl-α-L-fucopyranosyl-(1→2)-3,6-di-O-benzyl-4-O-methyl-β-D-galactopyranosyl-(1→3)-4,6-di-O-acetyl-2-azide-2-deoxy-α-D-galactopyranoside (15).
Compound 15 was prepared from 14 (157 mg, 0.13 mmol) as described for preparation of 9. The product was purified by silica gel column chromatography (2:1 hexane-ethyl acetate) to give 15 (148 mg, 95%). (17) . Compound 17 was prepared from 16 (50.9 mg, 52.8 μmol) as described for preparation of 11. , H-2'), 3.95-3.88 (m, 3H, H-2, H-6b, H-4'), 3.72-3.68 (m, 1H,  OCH 2 CH 2 a), 3.66-3.55 (m, 7H, H-5, H-5', H-6'a, H-6'b, OCH 3 ), 3.51-3.47 (m, 2H, H-3 ', OCH 2 CH 2 b), 2.32 (t, 2H, J = 7.4 Hz), 1.69- 1.61 (m, 4H), 1.43-1.38 (m, 2H) . 13 C-NMR (CDCl 3 ): δ 174.1, 138.6,  138.4, 137.9, 137.7, 128.8, 128.5, 128.4, 128.3, 128.2, 128.1, 127.9, 127.8, 127.7, 127.6, 126.3, 105.2  (C-1') , 100.8 (CHPh) 98.5 (C-1), 81.8 (C-3'), 76.0 (C-4), 75.7 (C-3), 74.6 (PhCH 2 ), 73.9 (C-5'), 73.7 (C-4'), 73.5 (PhCH 2 ), 73.0 (PhCH 2 ), 71.5 (C-2'), 69.2 (C-6'), 69.1 (C-6), 68.3 (OCH 2 CH 2 ), 63.1 (C-5), 58.9 (C-2), 51. 
5-(Methoxycarbonyl)pentyl 3,4-di-O-benzoyl-α-L-fucopyranosyl-(1→2)-4-O-methyl-β-D-galactopyranosyl-(1→3)-4,6-di-O-acetyl-2-acetamide-2-deoxy-α-D-galactopyranoside (16). Compound
5-(Methoxycarbonyl)pentyl α-L-fucopyranosyl-(1→2)-4-O-methyl-β-D-galacto-pyranosyl-(1→3)-2-acetamide-2-deoxy-α-D-galactopyranoside
5-(Methoxycarbonyl)pentyl 2-O-benzoyl-3,4,6-tri-O-benzyl-α-D-galactopyranosyl-(1→3)-2-azide-4,6-Obenzylidene-2-deoxy-β-D-galactopyranoside (19). Compound
5-(Methoxycarbonyl)pentyl 3,4,6-tri-O-benzyl-α-D-galactopyranosyl-(1→3)-2-azide-4,6-O-benzylidene-2-deoxy-β-D-galactopyranoside (20). Compound
5-(Methoxycarbonyl)pentyl 3,4-di-O-benzoyl-2-O-methyl-α-L-fucopyranosyl-(1→2)-3,4,6-tri-O-benzyl-β-D-galactopyranosyl-(1→3)-2-azide-4,6-O-benzylidene-2-deoxy-α-D-galactopyranoside (21).
Compound 21 was prepared from 20 (119 mg, 0.14 mmol) and 7 (133 mg, 0.28 mmol) as described for preparation of 8. 
5-(Methoxycarbonyl)pentyl 3,4-di-O-benzoyl-2-O-methyl-α-L-fucopyranosyl-(1→2)-3,4,6-tri-O-benzyl-β-D-galactopyranosyl-(1→3)-4,6-di-O-acetyl-2-azide-2-deoxy-α-D-galactopyranoside (22). Compound 22
was prepared from 21 (130 mg, 106 μmol) as described for preparation of 9. The product was purified by silica gel column chromatography (2:1 hexane-ethyl acetate) to give 22 (114 mg, 88.4%). 
5-(Methoxycarbonyl)pentyl 3,4-di-O-benzoyl-2-O-methyl-α-L-fucopyranosyl-(1→2)-3,4,6-tri-O-acetyll-β-D-galactopyranosyl-(1→3)-4,6-di-O-acetyl-2-acetamide-2-deoxy-α-D-galactopyranoside (23)
5-(Methoxycarbonyl)pentyl 3,4-di-O-benzoyl-2-O-benzyl-α-L-fucopyranosyl-(1→2)-3,4,6-tri-O-benzyl-β-D-galactopyranosyl-(1→3)-2-azide-4,6-O-benzylidene-2-deoxy-α-D-galactopyranoside (25).
Compound 25 was prepared from 20 (152 mg, 0.18 mmol) and 13 (197 mg, 0.356 mmol) as described for preparation of 8. The product was purified by silica gel column chromatography (2:1 hexane-ethyl acetate) to give 25 (176 mg, 76%). 
5-(Methoxycarbonyl
Compound 26 was prepared from 25 (176 mg, 0.14 mmol) as described for preparation of 9. The product was purified by silica gel column chromatography (2:1 hexane-ethyl acetate) to give 26 (113 mg, 64%). 
5-(Methoxycarbonyl)pentyl 3,4-di-O-benzoyl-α-L-fucopyranosyl-(1→2)-3,4,6-tri-O-acetyl-β-Dgalactopyranosyl-(1→3)-4,6-O-acetyl-2-acetamide-2-deoxy-α-D-galactopyranoside (27). Compound 27
was prepared from 26 (176 mg, 135 μmol) as described for preparation of 23. The product was purified by silica gel column chromatography (5:1 toluene-acetone) to give 27 (110 mg, 74%). 
5-(Methoxycarbonyl)pentyl 3,4-di-O-benzoyl-2-O-methyl-α-L-fucopyranosyl-(1→2)-4-O-methyl-β-Dgalactopyranoside (32)
5-(Methoxycarbonyl)pentyl 2-O-methyl-α-L-fucopyranosyl-(1→2)-4-O-methyl-β-D-galactopyranoside (33).
Compound 33 was prepared from 32 (88.2 mg, 0.13 mmol) as described for preparation of 11. 
